Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 5/20 | 0.44 |
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041077 | 1.00 | MGLL (0.54) | MGLLMAPTSMN1; SMN2NPSR1NPC1 | |
| SCHEMBL29400674 | 1.00 | MGLL (0.54) | MGLLMAPTSMN1; SMN2NPSR1NPC1 | |
| SCHEMBL31519043 | 0.97 | MGLL (0.54) | MGLLMAPTSMN1; SMN2NPSR1NPC1 | |
| SCHEMBL14299860 | 0.94 | MGLL (0.49) | MGLLMAPTSMN1; SMN2NPSR1NPC1 | |
| SCHEMBL18560008 | 0.90 | KLK7 (0.57) | MAPTTGM2CA1CA2KLK7 | |
| SCHEMBL7302025 | 0.90 | TGM2 (0.56) | MGLLMAPTNPSR1TGM2TDP1 | |
| SCHEMBL13041082 | 0.90 | KLK7 (0.57) | MAPTTGM2CA1CA2KLK7 | |
| SCHEMBL30684686 | 0.89 | MGLL (0.58) | MGLLMAPTSMN1; SMN2NPSR1NPC1 | |
| SCHEMBL10866363 | 0.89 | MAPT (0.49) | MGLLMAPTSMN1; SMN2NPSR1NPC1 | |
| SCHEMBL3401322 | 0.89 | MGLL (0.59) | MGLLMAPTNPSR1TGM2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3915587-B1 | IMPROVED CELL-TARGETING BINDING MOLECULE | SAPREME TECH BV (NL) | 2026-03-25 | — | — | EP | disclosed |
| US-20260000783-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | SAPREME TECHNOLOGIES B.V. (NL) | 2026-01-01 | — | — | US | disclosed |
| EP-4647436-A2 | BIOLOGICALLY ACTIVE CLUSTER OF MOLECULES | Sapreme Technologies B.V. (NL) | 2025-11-12 | — | — | EP | disclosed |
| US-12453782-B2 | Antibody-oligonucleotide conjugate | SAPREME TECHNOLOGIES B.V. (NL) | 2025-10-28 | — | — | US | disclosed |
| EP-3897735-B1 | BIOLOGICALLY ACTIVE CLUSTER OF MOLECULES | SAPREME TECH BV (NL) | 2025-10-22 | — | — | EP | disclosed |
| US-20250302983-A1 | Saponin Conjugates | SAPREME TECHNOLOGIES B.V. (NL) | 2025-10-02 | — | — | US | disclosed |
| US-12421276-B2 | Methods of treating neurodegenerative disease with substituted n-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide analogues | ATHIRA PHARMA, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4588523-A2 | IMPROVED CELL-TARGETING BINDING MOLECULE | Sapreme Technologies B.V. (NL) | 2025-07-23 | — | — | EP | disclosed |
| US-20250195682-A1 | IMPROVED CELL-TARGETING BINDING MOLECULE | SAPREME TECHNOLOGIES B.V. (NL) | 2025-06-19 | — | — | US | disclosed |
| EP-4241847-B1 | IMPROVED CELL-TARGETING BINDING MOLECULE | SAPREME TECH BV (NL) | 2025-06-04 | — | — | EP | disclosed |
| WO-2011140376-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | PROLYNX LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20090269298-A1 | AGENT FOR THE PREVENTION AND TREATMENT OF SEXUALLY TRANSMITTED DISEASES-I | STARPHARMA PTY LTD. | 2009-10-29 | — | — | US | disclosed |
| US-7589056-B2 | Agent for the prevention and treatment of sexually transmitted diseases-I | STARPHARMA PTY. LTD. (AU) | 2009-09-15 | — | — | US | disclosed |
| EP-1399499-B1 | AGENT FOR THE PREVENTION AND TREATMENT OF SEXUALLY TRANSMITTED DISEASES-I | STARPHARMA PTY LTD (AU) | 2009-03-18 | — | — | EP | disclosed |
| US-20050008611-A1 | Agent for the prevention and treatment of sexually transmitted diseases-I | STARPHARMA PTY LTD (AU) | 2005-01-13 | — | — | US | disclosed |
| EP-0636028-B1 | SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM COMPRISING AN AMPHIPHATIC CATIONIC PEPTIDE | UNIV CALIFORNIA (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1236473-A2 | Self-assembling polynucleotide delivery system | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-09-04 | — | — | EP | disclosed |
| US-4410688-A | POLYAMIDES FROM DIAMINOCARBOXYLIC ACIDS | ALLIED CORPORATION (US) | 1983-10-18 | — | — | US | disclosed |
| US-4360646-A | Preparation of lysine based macromolecular highly branched homogeneous compound | ALLIED CORPORATION (US) | 1982-11-23 | — | — | US | disclosed |
| US-4289872-A | SURFACE MODIFYING AGENTS, METAL CHELATING AGENTS, SUBSTRATES FOR DRUGS | ALLIED CORPORATION (US) | 1981-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302983-A1 | Saponin Conjugates | EPCAM, CD47, SHBG | MGLL 4483/4885MAPT 4204/4885SMN1; SMN2 4094/4885 |
| US-20260000783-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | EPCAM, CD47, FCGR3B | MGLL 4330/4885MAPT 3753/4885SMN1; SMN2 3134/4885 |
| US-12421276-B2 | Methods of treating neurodegenerative disease with substituted n-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide analogues | AADAT, ABAT, IAPP | MGLL 707/4885MAPT 48/4885SMN1; SMN2 30/4885 |
| US-12453782-B2 | Antibody-oligonucleotide conjugate | CD40, FCGR1A, TNFSF10 | MGLL 3151/4885MAPT 4452/4885SMN1; SMN2 3219/4885 |
| US-20050008611-A1 | Agent for the prevention and treatment of sexually transmitted diseases-I | DNPEP, CTSA, TLR1 | MGLL 1559/4885MAPT 2210/4885SMN1; SMN2 3197/4885 |
| US-20250195682-A1 | IMPROVED CELL-TARGETING BINDING MOLECULE | EPCAM, CD47, CD74 | MGLL 4339/4885MAPT 4039/4885SMN1; SMN2 3978/4885 |
| US-20090269298-A1 | AGENT FOR THE PREVENTION AND TREATMENT OF SEXUALLY TRANSMITTED DISEASES-I | DNPEP, CTSA, TLR1 | MGLL 1559/4885MAPT 2210/4885SMN1; SMN2 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.